'Seeds of change' sprout into higher projected return on investments for the biopharma industry, according to Deloitte
Since 2010, Deloitte has been tracking the return on investment that a handful of top biopharma companies might expect to see from their late-stage assets. Last year, the company noted “seeds of change” following a six-year decline in average internal rate of returns.
Deloitte’s latest report indicates the trend has continued this year, as projected R&D returns have risen from 2.7% to 7%, the largest annual increase since the study began in 2010.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.